These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. Midbrain muscarinic receptors modulate morphine-induced accumbal and striatal dopamine efflux in the rat. Miller AD; Forster GL; Yeomans JS; Blaha CD Neuroscience; 2005; 136(2):531-8. PubMed ID: 16216430 [TBL] [Abstract][Full Text] [Related]
68. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway. Crawley JH Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706 [TBL] [Abstract][Full Text] [Related]
69. Electrophysiological evidence of modulatory interaction between dopamine and cholecystokinin in the nucleus accumbens. Yim CC; Mogenson GJ Brain Res; 1991 Feb; 541(1):12-20. PubMed ID: 2029612 [TBL] [Abstract][Full Text] [Related]
70. PD-135,158, a cholecystokinin(B) antagonist, enhances latent inhibition in the rat. Gracey DJ; Bell R; King DJ Pharmacol Biochem Behav; 2000 Mar; 65(3):459-63. PubMed ID: 10683486 [TBL] [Abstract][Full Text] [Related]
71. Immunohistochemical studies of mesolimbic dopaminergic neurons in Fischer 344 and Lewis rats. Harris HW; Nestler EJ Brain Res; 1996 Jan; 706(1):1-12. PubMed ID: 8720486 [TBL] [Abstract][Full Text] [Related]
73. Cholecystokinin-8S increases dynorphin B, aspartate and glutamate release in the fronto-parietal cortex of the rat via different receptor subtypes. You ZB; Godukhin O; Goiny M; Nylander I; Ungerstedt U; Terenius L; Hökfelt T; Herrera-Marschitz M Naunyn Schmiedebergs Arch Pharmacol; 1997 May; 355(5):576-81. PubMed ID: 9151295 [TBL] [Abstract][Full Text] [Related]
74. The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCK(A) receptor antagonist: evidence for a novel CCK receptor subtype? van Kampen J; Stoessl AJ Neuropharmacology; 1997; 36(11-12):1679-88. PubMed ID: 9517439 [TBL] [Abstract][Full Text] [Related]
75. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260. O'Neill MF; Dourish CT; Iversen SD Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197 [TBL] [Abstract][Full Text] [Related]
76. Correlation between the discharge rate of non-dopamine neurons in substantia nigra and ventral tegmental area and the motor activity induced by apomorphine. Olds ME Neuroscience; 1988 Feb; 24(2):465-76. PubMed ID: 3362349 [TBL] [Abstract][Full Text] [Related]
77. Cholecystokinin is necessary for the expression of morphine conditioned place preference. Mitchell JM; Bergren LJ; Chen KS; Fields HL Pharmacol Biochem Behav; 2006 Dec; 85(4):787-95. PubMed ID: 17196636 [TBL] [Abstract][Full Text] [Related]
78. Evidence for an endogenous cholecystokininergic balance in social memory. Lemaire M; Piot O; Roques BP; Böhme GA; Blanchard JC Neuroreport; 1992 Oct; 3(10):929-32. PubMed ID: 1421101 [TBL] [Abstract][Full Text] [Related]
79. Influence of cholecystokinin on central monoaminergic pathways. Widerlöv E; Kalivas PW; Lewis MH; Prange AJ; Breese GR Regul Pept; 1983 May; 6(2):99-109. PubMed ID: 6308717 [TBL] [Abstract][Full Text] [Related]
80. SR146131, a cholecystokinin-A receptor agonist, antagonizes prepulse inhibition deficits produced by dizocilpine and DOI. Shilling PD; Feifel D Psychopharmacology (Berl); 2002 Nov; 164(3):285-93. PubMed ID: 12424552 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]